Novartis/BeiGene Opt For PD-1/TIGIT Combo For NSCLC In US
Defocus On 2L Monotherapy
Executive Summary
The two companies have ceased to seek US approval for tislelizumab as a monotherapy for second-line non-small cell lung cancer and are instead seeming to pin their hopes on a combination with BeiGene’s anti-TIGIT antibody ociperlimab in the first-line setting.
You may also be interested in...
Applications Heavily Reliant On Foreign Data Get Positive Signals In US FDA Reviews
Agency has notably rejected some NDAs that relied solely on Chinese data, but a positive advisory committee for Geron’s proposed anemia treatment imetelstat and approval for BeiGene’s anti-PD-1 antibody Tevimbra suggest that using a lot of foreign data could be OK.
US Tevimbra Approval Validates BeiGene’s Asia-Heavy Global Trial Approach
BeiGene's first US approval for Tevimbra (tislelizumab), based on an Asia-heavy global study, is expected to pave the way for the biopharma to win two more approvals within 2024.
BeiGene’s Tislelizumab Delivers With OS Data In Broad Gastric Cancer Population
The PD-L1 inhibitor partnered with Novartis improved overall survival in combination with chemotherapy in gastric cancer patients regardless of PD-L1 status.